Literature DB >> 28088904

Fc-fusion Proteins in Therapy: An Updated View.

Reza Jafari1, Naime M Zolbanin2, Houshang Rafatpanah3, Jafar Majidi4, Tohid Kazemi5.   

Abstract

Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor (FcRn) thereby rescuing it from degradation. The first therapeutic Fc-fusion protein was introduced for the treatment of AIDS. The molecular designing is the first stage in production of Fc-fusion proteins. The amino acid residues in the Fc region and linked protein are very important in the bioactivity and affinity of the fusion proteins. Although, therapeutic monoclonal antibodies are the top selling biologics but the application of therapeutic Fc-fusion proteins in clinic is in progress and among these medications Etanercept is the most effective in therapy. At present, eleven Fc-fusion proteins have been approved by FDA. There are novel Fc-fusion proteins which are in pre-clinical and clinical development. In this article, we review the molecular and biological characteristics of Fc-fusion proteins and then further discuss the features of novel therapeutic Fc-fusion proteins. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Fc region; Fc-fusion proteins; FcRn; antibody; immunotherapy

Mesh:

Substances:

Year:  2017        PMID: 28088904     DOI: 10.2174/0929867324666170113112759

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  18 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.

Authors:  Eleonora Trotta; Paul H Bessette; Stephanie L Silveria; Lauren K Ely; Kevin M Jude; Duy T Le; Charles R Holst; Anthony Coyle; Marc Potempa; Lewis L Lanier; K Christopher Garcia; Natasha K Crellin; Isaac J Rondon; Jeffrey A Bluestone
Journal:  Nat Med       Date:  2018-06-25       Impact factor: 53.440

3.  Optimized lactoferrin as a highly promising treatment for intracerebral hemorrhage: Pre-clinical experience.

Authors:  Xiurong Zhao; Marian Kruzel; Shun-Ming Ting; Guanghua Sun; Sean I Savitz; Jaroslaw Aronowski
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-21       Impact factor: 6.200

Review 4.  New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals.

Authors:  Mark A Jarosinski; Yen-Shan Chen; Nicolás Varas; Balamurugan Dhayalan; Deepak Chatterjee; Michael A Weiss
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

Review 5.  Engineered antibody fusion proteins for targeted disease therapy.

Authors:  Aliyah B Silver; Elissa K Leonard; Joseph R Gould; Jamie B Spangler
Journal:  Trends Pharmacol Sci       Date:  2021-10-25       Impact factor: 14.819

6.  Modulation of TDM-induced granuloma pathology by human lactoferrin: a persistent effect in mice.

Authors:  Jeffrey K Actor; Thao K T Nguyen; Agnieszka Wasik-Smietana; Marian L Kruzel
Journal:  Biometals       Date:  2022-08-17       Impact factor: 3.378

7.  Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.

Authors:  Huan Xu; Mingyang Shi; Changsheng Shao; Hao Li; Jing Wu; Yin Yu; Fang Fang; Yugang Guo; Weihua Xiao
Journal:  Microb Cell Fact       Date:  2021-06-09       Impact factor: 5.328

8.  Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.

Authors:  Alicja M Sochaj-Gregorczyk; Patryk Ludzia; Emilia Kozdrowska; Piotr Jakimowicz; Aleksandra Sokolowska-Wedzina; Jacek Otlewski
Journal:  Int J Mol Sci       Date:  2017-08-03       Impact factor: 5.923

Review 9.  Kinase-targeted cancer therapies: progress, challenges and future directions.

Authors:  Khushwant S Bhullar; Naiara Orrego Lagarón; Eileen M McGowan; Indu Parmar; Amitabh Jha; Basil P Hubbard; H P Vasantha Rupasinghe
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

10.  The engineered expression of secreted HSPB5-Fc in CHO cells exhibits cytoprotection in vitro.

Authors:  Jing Li; Jingjing Yu; Wenxian Xue; Huili Huang; Longjun Yan; Fan Sang; Shuangshuang An; Jing Zhang; Mingli Wang; Jun Zhang; Hui Li; Xiukun Cui; Jiang He; Yanzhong Hu
Journal:  BMC Biotechnol       Date:  2021-06-14       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.